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Abstract 
Multiple myeloma (MM) is an incurable B-cell malignancy, requiring new therapeutic 
strategies. We have found that synthetic alkyl-lysophospholipids (ALPs) edelfosine and 
perifosine induced apoptosis in MM cell lines and patient MM cells, whereas normal B 
and T lymphocytes were spared. ALPs induced recruitment of Fas/CD95 death receptor, 
Fas-associated death domain-containing protein and procaspase-8 into lipid rafts, 
leading to the formation of the death-inducing signaling complex (DISC) and apoptosis. 
TNF-related apoptosis-inducing ligand receptor-1/death receptor 4 (TRAIL-R1/DR4) 
and TRAIL-R2/DR5, as well as Bid were also recruited into lipid rafts, linking death 
receptor and mitochondrial signaling pathways. ALPs induced mitochondrial 
cytochrome c release. Bcl-XL overexpression prevented cytochrome c release and 
apoptosis. A Fas/CD95-deficient MM subline expressing DR4 and DR5 was resistant to 
edelfosine. Fas/CD95 retrovirus transduction bestowed edelfosine sensitivity in these 
cells. A Fas/CD95 mutant lacking part of the intracellular domain was ineffective. Lipid 
raft disruption prevented ALP-induced Fas/CD95 clustering, DISC formation and 
apoptosis. ALP-induced apoptosis was Fas/CD95 ligand (FasL/CD95L)-independent. 
ALP-induced recruitment of death receptors in lipid rafts potentiated MM cell killing by 
FasL/CD95L and TRAIL. These data uncover a novel lipid raft-mediated therapy in 
MM involving concentration of death receptors in membrane rafts, with Fas/CD95 
playing a major role in ALP-mediated apoptosis. 
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Introduction 
Multiple myeloma (MM) is a lymphoid cancer of terminally differentiated B-cell 
lineage or plasma cells that accounts for 10% of all hematologic cancers 
1
, ranking as 
the second most common blood cancer, after non-Hodgkin lymphoma 
2
. MM, currently 
an incurable disease, is characterized as a tumor composed of long-surviving rather than 
fast-growing malignant plasma cells 
3,4
. This implies that a therapeutic potential may lie 
in potentiating apoptosis. 
Synthetic alkyl-lysophospholipids (ALPs) constitute a heterogeneous group of 
unnatural lipids with promising anticancer activity. Unlike most conventional 
chemotherapeutic drugs, ALPs do not target the DNA, but act at the level of cell 
membranes affecting apoptotic signaling 
5-7
. The prototype of these ALPs is 1-O-
octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3, edelfosine) that 
shows selective apoptosis in tumor cells, whereas normal cells are spared 
8
. Examples of 
clinically relevant oral anti-cancer ALPs include the prototypic compound edelfosine 
and the novel drug octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate (D-21266, 
perifosine) 
5,9
. We have found that edelfosine induces selectively apoptosis in leukemic 
cells by its preferential incorporation into cancer cells 
8,10,11
, leading to the intracellular 
activation of the death receptor Fas/CD95 by its recruitment together with downstream 
signaling molecules into clusters of lipid rafts 
10-12
. This edelfosine-induced Fas/CD95 
intracellular activation and concentration in lipid rafts was independent of its ligand 
Fas/CD95 ligand (FasL/CD95L) and did not require sphingomyelinase activation 
10,11
. 
Edelfosine was the first antitumor drug reported to act through a novel mechanism 
involving Fas/CD95 translocation into lipid rafts 
12
, and recent findings further support 
that co-clustering of Fas/CD95 with lipid rafts is a novel and efficient mode of inducing 
apoptosis in cancer chemotherapy 
11-17
. 
Fas/CD95 shares with other death receptors of the tumor necrosis factor (TNF) 
receptor superfamily, such as TNF-related apoptosis-inducing ligand (TRAIL) 
receptors, the capacity to transmit apoptosis signals through the presence of a death 
domain in its cytoplasmic portion after receptor engagement with its ligand or an 
agonistic antibody 
18
. Unlike the intracellular regions of other transmembrane receptors 
involved in signal transduction, the death domain does not possess enzymatic activity, 
but mediates signaling through protein-protein interactions. Stimulation of Fas/CD95 
results in receptor aggregation and recruitment of the adaptor molecule Fas-associated 
death domain-containing protein (FADD) through interaction between its own death 
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domain and the clustered receptor death domains. FADD, in turn, contains a death 
effector domain that binds to an analogous domain repeated in tandem within the 
zymogen form of procaspase-8, forming the so-called death-inducing signaling complex 
(DISC), made up of aggregated Fas, FADD and procaspase-8 
19
. Upon recruitment by 
FADD, procaspase-8 oligomerization drives its activation through self-cleavage, 
activating downstream effector caspases and leading to apoptosis. We and others have 
recently reported that Fas is translocated into lipid raft clusters during Fas-mediated 
apoptosis 
10-12,16,17,20-22
. Thus, aggregation of membrane platforms where Fas molecules 
are brought together is suggested to facilitate DISC formation and thereby potentiate 
Fas signaling 
10-12,16,17,20-23
. Lipid rafts are membrane microdomains highly enriched in 
cholesterol and sphingolipids varying in size from 50-70 nm, and the proteins located in 
these microdomains are severely limited in their ability to freely diffuse over the plasma 
membrane 
24
. Thus, raft association tends to concentrate specific proteins within plasma 
membrane microdomains, affecting protein function 
25
. 
Because ALPs are potent apoptotic inducers in cancer cells and MM is a slowly 
proliferating tumor of long-lived plasma cells, we reasoned that this disease could be 
particularly suitable for the therapeutic use of ALPs. Thus, we investigated the action of 
ALPs on MM and analyzed the role of death receptor and lipid raft co-clustering in their 
antimyeloma action. 
 
Materials and Methods 
Reagents 
Edelfosine was from INKEYSA (Barcelona, Spain). Perifosine was from Zentaris 
(Frankfurt, Germany). RhTRAIL and rhFasL were from Alexis Biochemicals (Lausen, 
Switzerland). All other chemicals were from Sigma Chemical (St Louis, MO), Roche 
Biochemicals (Mannheim, Germany) or Merck (Darmstadt, Germany). 
 
Cell lines and primary cells 
Human MM cell lines MM144, MM1S, MM1R, RPMI-8226 and OPM-2 (provided by 
A. Pandiella, Centro de Investigación del Cáncer, Salamanca, Spain), as well as Jurkat 
T lymphoid and JY B lymphoid leukemia cell lines (American Type Culture 
Collection), were cultured in RPMI-1640 medium containing 10% (v/v) heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 
μg/mL streptomycin at 37ºC in humidified 95% air and 5% CO2. 
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Heparanized bone marrow aspirates, obtained from patients with newly 
diagnosed MM and after signing informed consent, were provided by the Hematology 
Department of the University Hospital (Salamanca, Spain). Mononuclear cells were 
isolated by Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden) density gradient 
centrifugation, and subjected to positive selection using MACS CD138 MicroBeads and 
MACS LS separation columns (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Purified CD138-positive tumor cells (>95% plasma cells) and CD138-negative 
nontransformed cells were resuspended in RPMI-1640/10% FBS, and used immediately 
for experiments. 
 To isolate normal peripheral blood lymphocytes (PBLs), mononuclear cells were 
obtained from fresh human peripheral blood from healthy volunteers by centrifugation 
on Ficoll-Hypaque density gradients, washed with phosphate-buffered saline (PBS), and 
resuspended in RPMI-1640/10% FBS as described 
26
. Monocytes were depleted by 
culture dish adherence after overnight incubation. Nonadherent cells (lymphocytes) 
were washed with PBS and collected by centrifugation. PBL preparations were typically 
69-74% CD3
+
, 25-28% CD19
+
, and <0.4% CD14
+
. To further purify T-cells, 
nonadherent cells were washed with PBS and passed twice through a nylon wool 
column to deplete residual B cells and monocytes. Purified T-cell preparations were 
typically >96% CD3
+
, <0.3 CD14
+
 and <4% CD25
+
. Normal PBL B cells were isolated 
by incubation of PBLs with CD19 magnetic beads, and then CD19
+
 B-cells were 
removed from the beads using CD19 DETACHaBEAD (Dynal Biotech, Oslo, Norway) 
following the manufaturer’s directions.  
Human umbilical vein endothelial cells were obtained by collagenase digestion 
of umbilical cord veins as described 
27
. 
 
Immunofluorescence flow cytometry 
Cell surface expression of death receptors was analyzed by flow cytometry in 4 x 10
5
 
cells as described previously 
10,28
, measuring both the percent of antigen positive cells 
and the mean fluorescence intensity (MFI), in a Becton Dickinson FACSCalibur
TM
 flow 
cytometer using an anti-Fas/CD95 SM1/1 IgG monoclonal antibody (Bender 
MedSystems, Vienna, Austria) and specific monoclonal antibodies against the 
extracellular domains of human DR4 and DR5 (R&D Systems, Minneapolis, MN). 
P3X63 myeloma culture supernatant, provided by F. Sánchez-Madrid (Hospital de La 
Princesa, Madrid, Spain), and an isotype-matched fluorescein isothiocyanate (FITC)-
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conjugated nonrelevant IgG monoclonal antibody (Becton Dickinson) were used as 
negative controls, leading to virtually identical background values. 
 
Confocal microscopy 
Cells were settled onto poly-L-lysine-coated slides and analyzed with a Zeiss LSM 510 
laser scan confocal microscope (Oberkochen, Germany) for membrane raft and protein 
visualization as described 
12
. Co-localization assays were analyzed by excitation of the 
corresponding fluorochromes in the same section. Negative controls, lacking the 
primary antibody or using an irrelevant antibody, showed no staining. 
 
Apoptosis assay 
Quantitation of apoptotic cells was calculated by flow cytometry as the percentage of 
cells in the sub-G1 region (hypodiploidy) in cell cycle analysis as previously 
described
29
. 
 The implication of Fas/CD95-FasL/CD95L interaction in ALP-induced 
apoptosis was evaluated as previously described 
10
. Cells (2.5 x 10
5
/mL) were pre-
incubated at 4ºC for 30 min in PBS + 1% bovine serum albumin (BSA) in the absence 
(controls) and in the presence of 100 ng/ml of the blocking anti-Fas/CD95 SM1/23 
IgG2b monoclonal antibody (Bender MedSystems, Vienna, Austria). Then, cells were 
resuspended at 5 x 10
5
/mL in complete RPMI-1640 culture medium in the absence or 
presence of the same amount of blocking anti-Fas/CD95 antibody, and treated with 50 
ng/mL of cytotoxic Fas agonistic anti-Fas/CD95 CH-11 monoclonal antibody (Upstate 
Biotechnology, Lake Placid, NY), 10 M edelfosine or 10 M perifosine at 37ºC for 24 
h. Then, cells were collected by centrifugation and analyzed for apoptosis by flow 
cytometry as above. Experiments performed with mock irrelevant isotype 
immunoglobulins had no effect.  
 
Edelfosine uptake 
Drug uptake was measured as described previously 
8
 after incubating cells (10
6
) with 10 
nmol [
3
H]edelfosine (10 M) for 6 h in RPMI-1640/10% FBS, and subsequent 
exhaustive washing (five times) with PBS + 2% BSA. [
3
H]edelfosine (specific activity, 
42 Ci/mmol) was synthesized by tritiation of the 9-octadecenyl derivative (Amersham 
Buchler, Braunschweig, Germany). 
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Lipid raft isolation and Western blotting  
Lipid rafts were isolated by using lysis conditions and centrifugation on discontinuous 
sucrose gradients as previously reported 
12
. In brief, 10
8 
cells were washed with ice-cold 
PBS and lysed for 60 min on ice with 1% Triton X-100 in TNEV buffer (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4) containing 1 mM 
phenylmethylsulfonyl fluoride (PMSF). Cells were then  homogenized with 10-15 
strokes in a Potter-Elvehjem tissue grinder. Nuclei and cellular debris were pelleted by 
centrifugation at 1000 rpm for 8 min. Then, 1 mL of cleared supernatant was mixed 
with 1 mL of 85% (w/v) sucrose in TNEV and transferred to the bottom of a Beckman 
14 x 95-mm centrifuge tube. The diluted lysate was overlaid with 6 mL of 35% (w/v) 
sucrose in TNEV and finally 3.5 mL 5% (w/v) sucrose in TNEV. The samples were 
centrifuged in an SW40 rotor at 38000 rpm for 18 h at 4ºC in a Beckman Optima LE-
80K ultracentrifuge (Beckman Instruments, Palo Alto, CA), and then 1-mL fractions 
were collected from the top of the gradient. To determine the location of distinct 
proteins in the discontinuous sucrose gradient, 20 L of the individual fractions were 
subjected to SDS-PAGE and immunoblotted using corresponding specific monoclonal 
antibodies and an enhanced chemiluminescence detection system (Amersham, 
Buckinghamshire, UK). The location of GM1-containing lipid rafts was determined 
using cholera toxin (CTx) B subunit conjugated to horseradish peroxidase as described 
previously 
30
. Proteins were identified using specific antibodies: anti-45-kDa Fas (C-20) 
rabbit polyclonal antibody, and anti-56-kDa DR4 (N-19), anti-48-kDa DR5 (N-19) and 
anti-23-kDa Bid (N-19) goat polyclonal antibodies (Santa Cruz Biotechnology, Santa 
Cruz, CA); anti-29-kDa FADD monoclonal antibody (clone-1) (BD Transduction 
Laboratories, Lexington, KY); and anti-55-kDa procaspase-8 (Ab-3) monoclonal 
antibody (Oncogene Research Products, Cambridge, MA). 
 
Coimmunoprecipitation 
MM144 cells (3-6 x 10
7
) were lysed with 500 L of lysis buffer (20 mM Tris-HCl, pH 
7.5, 100 mM KCl, 0.9% Triton X-100, 10% glycerol, 2 mM Na3VO4, 2 mM PMSF). 
Lysates were precleared with protein A-Sepharose, and immunoprecipitated with anti-
Fas (C-20) rabbit polyclonal antibody precoupled to protein A-Sepharose as previously 
described 
31
. Samples were subjected to SDS-PAGE and immunoblotted with specific 
antibodies against FADD and caspase-8. To immunoprecipate membrane raft proteins, 
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fractions 4-6 (200 l each) from the lipid raft isolation sucrose gradient were pooled and 
used for the coimmunoprecipitation assay as above. Lysates and membrane raft pools 
were also immunoprecipitated with P3X63 myeloma supernatant or with rabbit 
nonrevelant IgG that was isolated from pooled normal nonimmune rabbit serum, as 
negative controls, showing no signal. 
 
Cholesterol depletion and sequestration 
For cholesterol depletion, 2.5 x 10
5
 cells/mL were pretreated with 2.5 mg/mL methyl-β-
cyclodextrin (MCD) for 30 min at 37ºC in serum-free medium. Cells were then washed 
three times with PBS and resuspended in complete culture medium before ALP 
addition. For cholesterol sequestration, cells were treated with 0.3 μg/mL filipin for 1 h 
at 37ºC in serum-free medium, and then processed as above. 
 
Retroviral gene expression of Fas/CD95 
Construction of retroviral vectors 
Human Fas/CD95 and a 57 COOH-terminally truncated Fas/CD95 mutant (FasΔ57C) 
were cloned into the pLNCX2 retroviral vector (BD Biosciences Clontech, Palo Alto, 
CA) at the XhoI and SalI sites of the multiple cloning site. The resulting constructs were 
transformed to Escherichia coli DH5α cells. These constructs, as well as the empty 
vector, pLNCX2, were used in the subsequent transfection experiments. 
 
Transfection of the packaging cell line 
On the day before transfection the retroviral packaging cell line PT67 was plated on 60 
mm-diameter plates (1-2 x 10
6
 cells in 4 mL DMEM/10% FBS). Five minutes prior to 
transfection, 25 μM chloroquine was added to each plate. The transfection solution 
contained DNA (5-10 μg retroviral vector pLNCX2, pLNCX2-Fas or pLNCX2-
FasΔ57C),  31 μL 2 M CaCl2, 30 μL carrier DNA (200 ng/μL)  and H2O to 250 μL. 
After mixing, 250 μL of 2 x Hepes-buffered saline solution (pH 7.0) was added by 
bubbling, and the resulting solution was immediately dropped onto cells. The cells were 
then returned to the 37ºC incubator (5% CO2) for 24 h. Subsequently, the medium was 
changed to 3 mL of fresh culture medium containing 10% FBS, and 24-72 h later, the 
supernatant from transfected cells was centrifuged at 1000 x g for 5 min in a Sorvall 
T6000D centrifuge. 
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Infection of MM cells 
The target Fas/CD95-deficient OPM-2 cells were plated 12-18 h before infection at a 
cell density of 1-2 x 10
5
/60 mm-diameter plate in RPMI-1640/10% FBS. For infection, 
the medium from the retroviral packaging PT67 cells was collected and filtered through 
a 0.45-µm cellulose acetate sterile filter. Target cells were infected with 1 mL viral 
supernatant containing Polybrene at 8 μg/mL for 1 h. RPMI-1640/10% FBS medium (8 
mL) was added, and cells were grown for 24 h and then exposed to another round of 
infection. After the second round of infection, cells were grown for 2 to 3 days before 
selection with 400 μg/mL G418. 
 
Cell transfection with Bcl-XL  
The human MM144 cells were transfected by electroporation with the SFFV-Neo 
expression vector containing the human bcl-xL open reading frame driven by the long 
terminal repeat of the splenic focus-forming virus (pSFFV-bcl-xL). As a control, 
transfection was performed with empty SFFV-Neo plasmid. MM144 cells (4 x 10
7
) 
were subjected to electroporation at 500 V, 1700 µF, 72 ohm in a BTX electro cell 
manipulator 600 (Biotechnologies & Experimental Research Inc., SanDiego, CA), and 
selected by growth in the presence of 400 μg/mL of G418. 
 
Mitochondrial cytochrome c release 
Release of cytochrome c from mitochondria to cytosol was analyzed by Western blot as 
described previously 
32
, using antibodies against cytochrome c (7H8.2C12; BD 
Pharmingen, San Diego, CA) and cytochrome oxidase subunit II (12C4-F12; Molecular 
Probes, Eugene, OR).  
 
Results 
Edelfosine and perifosine induce selectively apoptosis in MM cells 
We found that the ALPs edelfosine and perifosine induced a potent apoptotic response 
in different MM cell lines (Figure 1A). There was a good correlation between the cell 
surface Fas/CD95 content in distinct MM cell lines and their sensitivity to undergo 
ALP-induced apoptosis (Figure 1, A and B). MM144 cells were more sensitive to ALPs 
than other cell lines, and they showed a higher cell surface Fas/CD95 content. In 
addition, we generated a subline from the OPM-2 cell line that lacked Fas/CD95 (Figure 
 10 
1B) after protracted cultures (>7 months) of parental cells, and these Fas/CD95-
deficient OPM-2 cells were rather ALP-resistant (Figure 1A). The level of Fas cell 
surface expression of the distinct MM cells was measured either by the percentage of 
Fas positive cells or the mean fluorescence intensity, showing a good correspondence 
between both values (Figure 1B). Both dexamethasone-sensitive MM1S cells and 
dexamethasone-resistant MM1R cells showed similar ALP-induced apoptotic cell death 
rates (Figure 1A), suggesting that these ALPs can circumvent dexamethasone 
resistance. 
Both ALPs also promoted apoptosis in primary cultures of MM cells derived 
from patients (Figure 1C), which were Fas/CD95-positive (data not shown). Normal 
mononuclear cells from the same patients were spared (Figure 1C). Edelfosine behaved 
somewhat more potent than perifosine in their capacity to induce apoptosis in both MM 
cell lines and primary cells, but both drugs were selective in their action for MM cells. 
Normal cells, including normal PBLs as well as normal purified B and T cells from 
healthy volunteers, were not affected by these drugs (Figure 1D). However, T lymphoid 
Jurkat and B lymphoid JY leukemic cells were very sensitive to the apoptotic action of 
ALPs (Figure 1D). In addition, normal human umbilical vein endothelial cells were also 
spared by these drugs (data not shown). 
 
 
Clustering of Fas/CD95 in lipid rafts is crucial to ALP-induced apoptosis in MM 
cells 
Following a time-course analysis we found that edelfosine and perifosine induced an 
apoptotic response in MM144 cells after about 15 h of incubation (Figure 2A). This 
effect was rather slow when compared to the rapid triggering of apoptosis following 
edelfosine treatment in T lymphoid Jurkat cells (>20% apoptosis after 6 h-incubation) 
33
. This timing in the induction of apoptosis was further corroborated by caspase-3 
activation in edelfosine-treated MM144 cells, as assessed by cleavage of procaspase-3 
into the p18 active form and cleavage of the typical caspase-3 substrate poly(ADP-
ribose) polymerase (PARP), using a polyclonal anti-caspase-3 antibody that recognized 
the 18-kDa subunit of active caspase-3, and an anti-PARP monoclonal antibody that 
detected both the 116-kDa intact form and the 85-kDa cleaved form of  PARP (Figure 
2B). 
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Because we have recently shown that edelfosine triggers apoptosis in T-
lymphoid and myeloid hematological tumor cells through a novel mechanism of action 
involving co-aggregation of Fas/CD95 and downstream signaling molecules with lipid 
rafts 
11,12
, we examined whether ALPs induced a similar apoptotic mechanism in MM 
cells that represent terminally differentiated B plasma cells. We found that edelfosine 
and perifosine promoted a potent co-clustering of lipid rafts and Fas/CD95 in MM144 
cells, as assessed by using the raft marker FITC-CTx B subunit that binds ganglioside 
GM1 
34
, mainly found in rafts 
35
 (Figure 2C). We also found a remarkable co-clustering 
of Fas/CD95 and lipid rafts in ALP-treated malignant cells derived from MM patients 
(data not shown). Disruption of lipid rafts by MCD or filipin, which interfere with 
protein association with lipid rafts by cholesterol depletion or sequestration, 
respectively 
12,25,36
, inhibited ALP-induced formation of Fas/CD95 clusters (Figure 3A) 
and apoptosis (Figure 3B) in MM cells. These results indicate that Fas/CD95 clustering 
in lipid rafts plays an important role in ALP-induced apoptosis in MM cells. 
 
ALP-induced translocation of death receptors and downstream signaling 
molecules into lipid rafts 
The above Fas/CD95 and lipid raft co-clustering was further confirmed by isolation of 
membrane rafts from MM144 cells, untreated and treated with either edelfosine or 
perifosine (Figure 4A). Lipid rafts were isolated based on their insolubility in Triton X-
100 lysis buffer at 4ºC and fractionated by discontinuous sucrose gradient centrifugation 
11,30
. GM1-containing lipid rafts, at the upper part (fractions 4-6) of the sucrose gradient 
(Figure 4A), were located using CTx B subunit conjugated to horseradish peroxidase 
30
. 
In addition to Fas/CD95, we also found that TRAIL receptors, DR4 and DR5, were 
translocated into lipid rafts in both edelfosine-and perifosine-treated cells (Figure 4A). 
Death receptor downstream signaling molecules FADD and procaspase-8 were also 
translocated into membrane rafts (Figure 4A). Interestingly, a portion of the active 
cleaved caspase-8 forms were also found in lipid rafts following ALP treatment (Figure 
4A). Our results indicate that edelfosine and perifosine induce a reorganization of the 
lipid raft protein content, translocating apoptotic proteins to these detergent-insoluble 
membrane domains. These data also show that the constituents of the DISC, the major 
apoptotic complex in death receptor signaling, are translocated into lipid rafts. This 
suggests that lipid rafts become enriched in apoptotic signaling molecules in ALP-
treated MM cells, harboring and bringing together major components of the death 
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receptor extrinsic pathway of apoptosis. We also found that Bid, which acts as a bridge 
between Fas/CD95 signaling and mitochondria 
37,38
, was translocated into lipid rafts 
following treatment of MM144 cells with edelfosine or perifosine (Figure 4A). A time-
course analysis showed that the translocation of the above proteins into lipid rafts 
occurred after 12-15 h incubation with the drugs (data not shown), i.e. by the time 
apoptosis was triggered (Figure 2A). We observed that edelfosine was more potent than 
perifosine in its ability to recruit apoptotic molecules into membrane rafts (Figure 4A). 
This differential protein translocating activity of the ALPs might explain the higher 
antitumor activity of edelfosine when compared to perifosine in MM cells (Figure 1, A 
and C). It is noteworthy to highlight the almost complete translocation of Fas/CD95, 
DR5, FADD and Bid to lipid rafts following edelfosine treatment (Figure 4A).   
 
Edelfosine induces DISC formation 
Because edelfosine induced translocation of Fas/CD95, FADD and caspase-8, into lipid 
rafts, we asked next whether edelfosine treatment of MM cells could lead to DISC 
formation. Following a time-course analysis, we found that, by the time (15-h 
incubation) edelfosine induced translocation of Fas/CD95 and downstream molecules 
into lipid rafts, coimmunoprecipitation assays showed the formation of DISC containing 
Fas/CD95, FADD and caspase-8 in edelfosine-treated MM144 cell extracts (Figure 4B). 
We also found DISC formation in membrane rafts isolated from edelfosine-treated 
MM144 cells (Figure 4C). Immunoprecipitation with either P3X63 myeloma 
supernatant (Figure 4C) or rabbit nonrelevant IgG (data not shown), used as negative 
controls, rendered no signal. Disruption of lipid rafts with MCD prevented DISC 
formation in edelfosine-treated cells (Figure 4B). DISC assembly was also detected in 
perifosine-treated cells, although to a lesser extent (data not shown). These data indicate 
that ALPs induce DISC formation through translocation and concentration of their 
constituents into lipid rafts. 
 
Fas/CD95 is required for ALP-induced apoptosis 
To further investigate the relevance of Fas/CD95 in ALP-mediated apoptosis in MM 
cells, we used an OPM-2 subline lacking Fas/CD95 (Figure 1A), that was generated 
after protacted cultures of parental OPM-2 cells. Fas/CD95-deficient OPM-2 cells 
expressed DR4 and DR5 at similar levels as the parental OPM-2 cells (Figure 5A), but 
were ALP-resistant (Figure 1A). This resistance was not due to a deficiency in drug 
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uptake, as Fas/CD95-deficient OPM-2 cells as well as the drug-sensitive MM144 cells 
and OPM-2 parental cells were able to take up the ether lipid at similar figures (Figure 
5B). ALP treatment did not restore Fas/CD95 expression in Fas/CD95-deficient OPM-2 
cells and did not increase Fas/CD95 cell surface expression in Fas/CD95-positive 
MM144 cells (Figure 5, C and D). These data are in agreement with our previous 
findings showing that edelfosine treatment did not upregulate Fas/CD95 expression in 
leukemic cells 
10,11
. When Fas/CD95 was ectopically expressed in Fas/CD95-deficient 
OPM-2 cells through retroviral transduction, we found a high cell surface expression of 
Fas/CD95 and cells turned ALP sensitive (Figure 5, E and F) without affecting drug 
uptake (data not shown). Cells infected with empty virus behaved as uninfected cells 
(data not shown). Furthermore, we infected Fas/CD95-deficient OPM-2 cells with 
retroviruses containing a truncated version of human Fas/CD95 (Fas-deficient OPM-2-
FasΔ57C), lacking the 57 COOH-terminal amino acids (amino acids 279-335) that 
included part of the Fas/CD95 death domain 
39
. These Fas-deficient OPM-2-FasΔ57C 
cells expressed high levels of cell surface Fas/CD95, but were resistant to ALPs (Figure 
5, E and F). These data demonstrate that Fas/CD95 plays a critical role in edelfosine-
induced apoptosis. 
 
Involvement of mitochondria in ALP-induced apoptosis in MM cells 
Because Bid was translocated into lipid rafts in ALP-treated cells and edelfosine-
mediated apoptosis has been found to be dependent on mitochondrial signaling 
29,40,41
, 
we analyzed the putative implication of mitochondria in ALP-induced apoptosis in MM 
cells. Since Bcl-XL acts as a safeguard of mitochondria, preventing cytochrome c 
release and apoptosis 
42
, we examined the effect of overexpressing Bcl-XL in MM144 
cells to further analyze the role of mitochondria in the ALP antitumor action on MM. 
We stably transfected MM144 cells with pSFFV-bcl-xL (MM144-Bcl-XL), containing 
the human bcl-xL open reading frame, or with control pSFFV-Neo plasmid (MM144-
Neo). MM144-Neo cells behaved as non-transfected MM144 cells in all parameters 
studied. Western blot analysis showed that MM144-Neo cells expressed small levels of 
endogenous Bcl-XL, whereas a high expression of this protein was observed in MM144-
Bcl-XL cells (Figure 6A). MM144-Neo cells underwent apoptosis after treatment with 
either edelfosine or perifosine. However, overexpression of Bcl-XL by gene transfer in 
MM144 cells prevented ALP-induced apoptosis (Figure 6B). Both edelfosine and 
perifosine induced the appearance of cytochrome c in the cytosolic fraction of MM144 
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cells and its disappearance from the mitochondrial fraction by the time Fas/CD95 and 
Bid were translocated into lipid rafts (Figure 6C). This indicates that ALPs induce 
mitochondrial cytochrome c release. However, cytochrome c release was averted in 
MM144-Bcl-XL cells (Figure 6C). These data show that mitochondria are involved in 
ALP-induced MM cell death.  
 
ALP-induced apoptosis in MM cells is independent of FasL/CD95L 
Because Fas/CD95 was critical for the apoptotic effect of edelfosine and perifosine, we 
asked whether this apoptotic response was dependent on Fas/CD95-FasL/CD95L 
interactions. To examine the potential role of receptor-ligand interactions in ALP-
induced apoptosis, MM144 cells were preincubated with an anti-Fas/CD95 blocking 
monoclonal antibody (SM1/23), which abrogates Fas/CD95-FasL/CD95L-mediated 
killing. Preincubation with the blocking SM1/23 anti-Fas/CD95 antibody totally 
prevented apoptosis induced by the agonistic CH-11 anti-Fas/CD95 monoclonal 
antibody, but it did not affect edelfosine- and perifosine-induced apoptosis (Figure 7A). 
This suggests that Fas/CD95-FasL/CD95L interactions are not required for ALP-
induced apoptosis in MM cells. 
 
ALP-elicited recruitment of death receptors in lipid rafts potentiates apoptosis by 
death receptor ligands in MM cells 
Because edelfosine and perifosine induced a potent recruitment of death receptors and 
downstream signaling molecules in aggregated lipid rafts, thus concentrating these 
molecules in specific domains of the cell surface, we next examine whether this could 
further sensitize MM cells to death receptor ligands. We found that pretreatment of 
MM144 cells with edelfosine and perifosine potentiated significantly the antitumor 
responses to the extracellular engagement of death receptors by the action of their 
ligands (FasL/CD95L and TRAIL) or the agonistic cytotoxic anti-Fas/CD95 CH-11 
antibody (Figure 7B). 
 
Discussion 
The data reported here show that edelfosine and perifosine induce apoptosis in 
MM cells through the recruitment of the major death receptors Fas/CD95, DR4 and 
DR5, together with downstream signaling molecules, into lipid rafts. This represents a 
novel therapeutical approach for MM treatment. Our data show that this concentration 
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of death receptors and downstream apoptotic molecules in lipid rafts leads to DISC 
formation, setting off a sequence of events from the cell surface, independently of 
FasL/CD95L, that results in apoptosis. A critical role for Fas/CD95 in ALP-mediated 
apoptosis of MM cells can be inferred from this study. MM cells lacking Fas/CD95, but 
expressing DR4 and DR5, were resistant to ALPs. However, Fas/CD95 retrovirus 
transduction turned Fas/CD95-deficient cells into ALP-sensitive cells. Partial deletion 
of the death domain of Fas/CD95 was ineffective in restoring ALP sensitivity. These 
data indicate that the presence of Fas/CD95, independently of DR4 or DR5, is essential 
for ALP-mediated apoptosis in MM cells, and that the Fas/CD95 death domain is 
required for the apoptotic response. In addition, we have found that mitochondrial 
signaling is also involved in ALP-mediated apoptosis in MM cells, as assessed by ALP-
induced mitochondrial cytochrome c release and by prevention of ALP-induced 
mitochondrial cytochrome c release and apoptosis through Bcl-XL overexpression. The 
recruitment of Bid, a Fas/CD95-mitochondria linker 
37,38
, into lipid rafts following ALP 
treatment suggests a link between death receptor (extrinsic)- and mitochondrial 
(intrinsic)-signaling routes in ALP-induced apoptosis. These data, involving Fas/CD95 
and mitochondria in the ALP-induced apoptotic response in MM cells, are in agreement 
with previous reports in distinct tumor cell types showing that FADD dominant 
negative-expressing cells and Fas-deficient cells 
10,11,43
 as well as Bcl-2- and Bcl-XL-
overexpressing cells are ALP-resistant 
8,29
. Our data indicate that membrane rafts are 
critical for the action of edelfosine and perifosine as disruption of lipid rafts prevented 
Fas/CD95 clustering, DISC formation and apoptosis in ALP-treated MM cells. Thus, 
edelfosine and perifosine can be considered as efficient antitumor drugs acting through 
an unprecedented mechanism of action in the killing of MM cells by translocation and 
concentration of death receptors in lipid rafts. 
Our original studies demonstrated that co-clustering of Fas/CD95 and lipid rafts 
underlay the antitumor action of edelfosine in human leukemic cells 
12
, involving for the 
first time membrane rafts in Fas/CD95-mediated apoptosis and cancer chemotherapy. 
Subsequently, additional antitumor drugs, including resveratrol 
13
, cis-platinum 
14
, 
aplidin 
15
, and now the herein reported perifosine (this work), have been shown to 
induce similar co-clustering of Fas/CD95 and lipid rafts in their respective antitumor 
actions. Overall, these evidences suggest that the concentration of death receptors in 
lipid rafts is a crucial event in the regulation of apoptosis as well as in the antitumor 
action of distinct anti-cancer drugs, even though the extent of death receptor recruitment 
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in lipid rafts is highly dependent on both target cell and stimulus 
11,15-17
. Our data show 
that ALPs, especially edelfosine, exacerbate the recruitment of apoptotic molecules in 
lipid rafts in MM cells, rendering MM particularly suitable for ALP treatment. ALPs 
were able to recruit the three major death receptors, Fas/CD95, DR4 and DR5, together 
with adaptor molecules and downstream signaling molecules into lipid rafts in MM 
cells. These data square with recent findings showing redistribution of both Fas/CD95 
and TRAIL receptors in lipid rafts following cancer chemotherapy 
15,44
. 
The concentration of death receptors in lipid rafts following ALP treatment 
rendered MM cells more sensitive to the action of death receptor ligands. This is of 
particular importance for TRAIL, as this ligand shows a promising and selective 
antitumor action in different cancer cells 
45
 as well as antimyeloma activity 
46,47
. Thus, 
our findings indicate that edelfosine and perifosine are not only effective in the killing 
of MM cells, but they might be valuable drugs in combination therapy. In addition, 
MM1R cells, that showed resistance to dexamethasone treatment, were readily killed by 
these ALPs, suggesting that these agents could circumvent drug resistance in MM. 
Edelfosine has been shown to induce cell killing in MM cells resistant to doxorubicin, 
melphalan, mitoxantrone, VP-16, cytoxan, and vincristine 
48
, and perifosine has been 
reported to be cytotoxic to MM cells resistant to dexamethasone and melphalan 
49
. In 
addition, ALPs have been shown to be effective antitumor drugs in mouse MM models 
49,50
. 
A remarkable finding of the current study is that ALPs killed malignant MM 
cells, sparing normal cells derived from the same patient. Normal B and T cells as well 
as vascular endothelial cells were also spared. This agrees with previous reports 
showing that edelfosine is not toxic to normal cells at concentrations that kill a broad 
range of tumor cells 
8,10,51
.     
The present findings further support the notion that ALPs are effective in the 
treatment of hematologic malignancies, and that the induction of apoptosis through co-
clustering of death receptors in lipid rafts is a promising target in cancer therapy. 
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LEGENDS TO FIGURES 
 
Figure 1. Selective induction of apoptosis in MM cells by edelfosine and perifosine 
and correlation with Fas/CD95 cell surface expression. (A) MM cell lines were 
incubated for 24 and 48 h with 10 μM edelfosine or perifosine, and apoptosis was then 
quantitated as percentage of cells in the sub-G1 region in cell cycle analysis by flow 
cytometry. (B) Cell surface expression of Fas/CD95 in different MM cell lines was 
analyzed by flow cytometry. Percent of Fas-positive cells and MFI values were 
estimated using the P3X63 myeloma supernatant and an isotype-matched FITC-
conjugated nonrelevant IgG monoclonal antibody as negative controls. (C) Freshly 
isolated tumor MM cells and normal mononuclear cells (NC) from MM patients were 
incubated for the indicated times with 10 μM edelfosine or perifosine and analyzed for 
apoptosis as above. (D) Normal peripheral blood lymphocytes (PBL), purified PBL-T 
cells and purified PBL-B cells, as well as leukemic T lymphoid Jurkat (JK) and B 
lymphoid JY cells were incubated for the indicated times with 10 μM edelfosine or 
perifosine and analyzed for apoptosis as above. Untreated control cells were run in 
parallel. Data shown are means ± SD of four independent determinations. 
 
Figure 2. Time-course of ALP-induced apoptosis and co-clustering of membrane 
rafts and Fas/CD95 in edelfosine- and perifosine-treated MM cells. (A) MM144 
cells were incubated with 10 μM edelfosine or perifosine for the indicated times, and 
the proportion of cells in the sub-G1 region, representing apoptotic cells, was quantitated 
by flow cytometry. Data shown are means ± SD of three independent determinations. 
(B) MM144 cells were treated with 10 μM edelfosine for the indicated times, and 
analyzed by immunoblotting with an anti-caspase-3 antibody that recognized only the 
p18 subunit of active caspase-3, and with an anti-PARP antibody that detected both the 
116-kDa intact form of PARP and its p85 cleaved form. Data shown are representative 
of three experiments performed. (C) MM144 cells were either untreated (Control) or 
treated with 10 μM edelfosine or perifosine for 12 h, and then stained with FITC-CTx B 
subunit to identify lipid rafts (green fluorescence) and with a specific anti-Fas/CD95 
monoclonal antibody, followed by CY3-conjugated anti-mouse Ig antibody (red 
fluoresecence). Areas of colocalization between membrane rafts and Fas/CD95 in the 
merge panels are yellow. Images shown are representative of three independent 
experiments. Bar, 10 μm.   
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Figure 3. Disruption of membrane rafts inhibits ALP-induced Fas/CD95 clustering 
and apoptosis. MM144 cells were untreated (Control) or pretreated with MCD or 
filipin and then incubated with 10 μM edelfosine or perifosine for 12 h, and analyzed 
for Fas clustering by confocal microscopy (A), or for 24 h, and examined for the 
percentage of apoptotic cells by flow cytometry (B). Images shown in A are 
representative of three independent experiments. Bar, 10 μm. Data shown in B are 
means ± SD of three independent determinations. 
 
Figure 4. Recruitment of death receptors and downstream signaling molecules, 
and DISC formation in membrane rafts following ALP treatment of MM cells. (A) 
Untreated MM144 cells (Control) and MM144 cells treated with 10 μM edelfosine or 
perifosine for 15 h were lysed in 1% Triton X-100 and fractionated by centrifugation on 
a discontinuous sucrose density gradient. An equal volume of each collected fraction 
was subjected to SDS-PAGE before analysis of the indicated proteins using specific 
antibodies. The migration positions of the 55-kDa procaspase-8 as well as of the 
cleavage products (arrows) are denoted. Location of GM1-containing lipid rafts 
(fractions 4-6) was determined using CTx B subunit conjugated to horseradish 
peroxidase. (B) Fas/CD95 was immunoprecipitated from untreated control or 
edelfosine-treated (15 h) MM144 cell extracts. Fas/CD95 was also immunoprecipitated 
from MM144 cells pretreated with MCD to disrupt lipid rafts and then treated for 15 h 
with edelfosine. Immunoprecipitates were subjected to SDS-PAGE and immunoblotted 
with specific antibodies against Fas/CD95, FADD and caspase-8. (C) Fas/CD95 was 
immunoprecipitated from a pool of membrane raft-enriched fractions 4-6 from sucrose 
gradients similar to those shown in Figure 4A of edelfosine-treated MM144 cells. 
Immunoprecipitates were subjected to SDS-PAGE and immunoblotted with Fas/CD95-, 
FADD- and caspase-8-specific antibodies, respectively. Membrane raft-enriched 
fractions were also immunoprecipitated with P3X63 (X63) myeloma supernatant as a 
negative control, rendering no signal. Experiments shown are representative of three 
performed. 
 
Figure 5. Requirement of Fas/CD95 for ALP-induced apoptosis. (A) Cell surface 
expression of Fas/CD95, DR4 and DR5 in MM144, OPM-2 and Fas/CD95-deficient 
OPM-2 cells was determined by flow cytometry. Percent of positive cells for each death 
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receptor was estimated using the P3X63 myeloma culture supernatant and an isotype-
matched FITC-conjugated nonrelevant IgG monoclonal antibody as negative controls. 
(B) Edelfosine uptake was determined after incubating MM144, OPM-2 and Fas/CD95-
deficient OPM-2 cells with 10 nmol [
3
H]edelfosine for 6 h. (C, D) Fas/CD95-deficient 
OPM-2 and MM144 cells were untreated (Control) or treated with 10 μM edelfosine or 
perifosine for 12 h, and then Fas/CD95 cell surface expression was determined by flow 
cytometry as percent of Fas positive cells (C) or MFI (D). (E) Cell surface expression of 
Fas/CD95 was analyzed by immunofluorescence flow cytometry in Fas/CD95-deficient 
OPM-2 infected with empty virus (Fas-deficient OPM-2-vector), recombinant retrovirus 
containing human Fas/CD95 (Fas-deficient OPM-2-Fas) and recombinant retrovirus 
containing a truncated version of human Fas/CD95 (Fas-deficient OPM-2-FasΔ57C), 
lacking the 57 COOH-terminal amino acids. Percent of Fas/CD95-positive cells was 
estimated using the P3X63 myeloma supernatant and an isotype-matched FITC-
conjugated nonrelevant IgG monoclonal antibody as negative controls. (F) Induction of 
apoptosis in the above retrovirus-infected cells was determined by flow cytometry after 
a 24-h incubation with 10 μM edelfosine or perifosine. Untreated control cells were run 
in parallel. Data shown are means ± SD of three independent experiments. 
 
Figure 6. Prevention of ALP-induced cytochrome c release and apoptosis by 
overexpression of Bcl-XL. (A) Western blot analysis for Bcl-XL. Cell lysates from 
Neo-, (MM144-Neo) and Bcl-XL-transfected (MM144- Bcl-XL) MM144 cells were 
subjected to SDS-PAGE and immunoblotted with a Bcl-XL specific antibody to analyze 
Bcl-XL content. β-Actin was used as a loading control. Experiments shown are 
representative of three performed. (B) Neo-, and Bcl-XL-transfected MM144 cells were 
incubated for 24 h with 10 μM edelfosine or perifosine, and apoptosis was then 
quantitated as percentage of cells in the sub-G1 region by flow cytometry. Untreated 
control cells were run in parallel. Data shown are means ± SD of four independent 
determinations. (C) Western blot analysis of cytochrome c in cytosolic (CYT) and 
mitochondrial (MIT) extracts from MM144-Neo and MM144-Bcl-XL cells untreated (-) 
or treated (+) for 15 h with 10 μM edelfosine or perifosine. Cytochrome oxidase subunit 
II (Cyt ox.) was also analyzed in the  mitochondrial extracts as a control for 
mitochondrial protein loading. Experiments shown are representative of three 
performed. 
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Figure 7. ALP-induced apoptosis is independent of Fas/CD95-FasL/CD95L 
interaction and ALP treatment enhances cytotoxicity of death receptor ligands. (A) 
Fas/CD95-FasL/CD95L interaction is not required for ALP-induced apoptosis. MM144 
cells were untreated or preincubated with blocking SM1/23 antibody before addition of 
50 ng/mL cytotoxic anti-Fas/CD95 CH-11 monoclonal antibody, 10 μM edelfosine or 
10 μM perifosine. After 24 h incubation, apoptosis was quantitated by flow cytometry. 
(B) ALPs enhance cytotoxicity of Fas/CD95 and TRAIL ligands. MM144 cells were 
untreated or treated for 12 h with 10 μM edelfosine (EDLF) or perifosine (PERF), 
followed by addition of 50 ng/mL cytotoxic anti-Fas/CD95 CH-11 monoclonal 
antibody, 100 ng/mL FasL/CD95L, or 50 ng/mL TRAIL for 12 h. Untreated control 
cells and samples treated with 10 μM edelfosine or perifosine for 12 h and 24 h were 
also run in parallel. Apoptosis was then determined by flow cytometry. Data shown are 
means ± SD of three independent experiments. 
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Figure 1 (Gajate, C. and Mollinedo, F.) 
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Figure 2 (Gajate, C. and Mollinedo, F.) 
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Figure 3 (Gajate, C. and Mollinedo, F.) 
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Figure 4 (Gajate, C. and Mollinedo, F.) 
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Figure 5 (Gajate, C. and Mollinedo, F.) 
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Figure 6 (Gajate, C. and Mollinedo, F.) 
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Figure 7 (Gajate, C. and Mollinedo, F.) 
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